Soft earnings didn't appear to concern IVD Medical Holding Limited's (HKG:1931) shareholders over the last week. Our analysis suggests that while the profits are soft, the foundations of the business are strong.
View our latest analysis for IVD Medical Holding
SEHK:1931 Earnings and Revenue History September 23rd 2022
How Do Unusual Items Influence Profit?
Importantly, our data indicates that IVD Medical Holding's profit was reduced by CN¥29m, due to unusual items, over the last year. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. If IVD Medical Holding doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of IVD Medical Holding.
Our Take On IVD Medical Holding's Profit Performance
Because unusual items detracted from IVD Medical Holding's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Based on this observation, we consider it likely that IVD Medical Holding's statutory profit actually understates its earnings potential! Unfortunately, though, its earnings per share actually fell back over the last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. If you'd like to know more about IVD Medical Holding as a business, it's important to be aware of any risks it's facing. Be aware that IVD Medical Holding is showing 2 warning signs in our investment analysis and 1 of those makes us a bit uncomfortable...
This note has only looked at a single factor that sheds light on the nature of IVD Medical Holding's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
疲軟的收益似乎並不令人擔憂IVD醫療控股有限公司(HKG:1931)過去一週的股東人數。我們的分析表明,儘管利潤疲軟,但業務的基礎是強大的。
查看我們對IVD Medical Holding的最新分析
聯交所:1931年盈利及收入歷史2022年9月23日
不尋常的項目如何影響利潤?
重要的是,我們的數據顯示,由於異常項目,IVD Medical Holding去年的利潤減少了2900萬元人民幣。看到不尋常的項目讓公司損失利潤從來都不是件好事,但從好的方面來看,情況可能很快就會改善。當我們分析全球絕大多數上市公司時,我們發現重大的不尋常項目往往不會重複。畢竟,這正是會計術語所暗示的。如果IVD Medical Holding沒有看到這些不尋常的支出再次出現,那麼在其他條件相同的情況下,我們預計來年其利潤將會增加。
注:我們總是建議投資者檢查資產負債表的實力。點擊此處查看我們對IVD Medical Holding的資產負債表分析。
我們對IVD醫療控股公司利潤表現的看法
由於不尋常的項目減損了IVD Medical Holding去年的收益,你可以辯稱,我們可以預期本季度的業績會有所改善。基於這一觀察,我們認為IVD Medical Holding的法定利潤實際上很可能低估了其盈利潛力!然而,不幸的是,它的每股收益實際上在去年有所回落。本文的目的是評估我們可以在多大程度上依賴法定收益來反映公司的潛力,但還有很多東西需要考慮。如果你想更多地瞭解IVD Medical Holding作為一項業務,瞭解它面臨的任何風險是很重要的。請注意,IVD醫療控股公司正在展示我們的投資分析中的2個警告信號其中一件讓我們有點不舒服……
這份報告只關注了一個因素,它揭示了IVD Medical Holding的利潤性質。但如果你有能力將注意力集中在細枝末節上,總會有更多的東西需要發現。一些人認為,高股本回報率是高質量企業的良好標誌。所以你可能想看看這個免費擁有高股本回報率的公司的集合,或內部人士正在購買的這份股票清單。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。